New insights on CETP inhibition from genetic research and clinical trials
John Kastelein, MD, PhD
Exploring the role of a novel CETP inhibitor in lipid management
Roxana Mehran, MD
Diagnostic challenges for symptomatic obstructive HCM
Pablo García-Pavía, MD, PhD
Seeing the forest through the trees - Diagnosing and treating hypertrophic cardiomyopathy
Antonis Pantazis, MD
Carolyn Ho, MD
Improving quality of life in patients with HCM
Hypertrophic cardiomyopathy: What are the concerns?
Reassessing the role of triglycerides in residual cardiovascular risk
Richard Hobbs, MD
New paradigms in the prevention of ASCVD: The role of EPA and triglycerides
Lale Tokgözoğlu, MD
Victor Aboyans, MD, PhD
Integrating icosapent ethyl in preventive strategies: Practical guidance
The benefits of icosapent ethyl in addressing residual risk: What is the evidence?
What to do if potassium levels increase in HF?
Mikhail Kosiborod, MD
Breaking barriers in guideline-based RAASi therapy: Solving issues with hyperkalemia
Shelley Zieroth, MD
Aaron Wong, MD
Continuing foundational therapy in symptomatic HF: the key role of RAASi-based therapy
Practical experience and model for optimizing RAASi-based therapy in HF
Hypertrophic cardiomyopathy & heart failure: exploring new options
Rudolf de Boer, MD, PhD
Mariana Brandão, MD
Iacopo Olivotto, MD
Recognizing HCM and HF: making the diagnosis
Loading...
We’re glad to see you’re enjoying PACE-CME… but how about a more personalized experience?
Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.